Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
120
datasets available to search
ShareScore release 0.7.1
Dataset results
120 results for “Drug Repurposing”
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
<p>The Krogan Laboratory used affinity-purification mass spectrometry to identify 332 high confidence SARS-CoV-2-human protein-protein interactions, including 67 druggable human proteins or host factors targeted by 69 known drugs. Results may be relevant to antiviral drug production.</p>
Perturbation response scanning of drug-target networks: Drug repurposing for multiple sclerosis
<p>This dataset contains molecular dynamics trajectories and corresponding input files used for simulations. The simulations were conducted using GROMACS and include detailed information about the simulated systems, such as the types of molecules, box dimensions, temperature, pressure, simulation time range, and time step.</p>
Associated code and data for "A network medicine approach for identifying diagnostic and prognostic biomarkers and exploring drug repurposing in human cancer (doi: 10.1016/j.csbj.2022.11.037)"
<p>This deposit contains the latest data, code, and analysis to recreate the results in the manuscript "A network medicine approach for identifying diagnostic and prognostic biomarkers and exploring drug repurposing in human cancer". Computational and Structural Biotechnology Journal 2023. <a href="https://www.researchgate.net/publication/365864472_A_network_medicine_approach_for_identifying_diagnostic_and_prognostic_biomarkers_and_exploring_drug_repurposing_in_human_cancer">DOI: 10.1016/j.csbj.2022.11.037</a>. </p> <p>If you use the code or data from this repository, please cite our publication.</p> <p> </p>
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Rec
ClinicalTrials.gov study NCT02770378. IPD Sharing: NO. Countries: 1. Publications: 2.
Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer
ClinicalTrials.gov study NCT03137186. IPD Sharing: NO. Countries: 1. Publications: 12.
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells
ClinicalTrials.gov study NCT06967831. IPD Sharing: UNDECIDED. Countries: 1. Publications: 6.
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
ClinicalTrials.gov study NCT05298670. IPD Sharing: Not stated. Countries: 1. Publications: 19.
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE
ClinicalTrials.gov study NCT05762146. IPD Sharing: NO. Countries: 1. Publications: 1.
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
ClinicalTrials.gov study NCT04339634. IPD Sharing: NO. Countries: 1. Publications: 5.
Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)
ClinicalTrials.gov study NCT04780854. IPD Sharing: NO. Countries: 1. Publications: 3.
iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study
ClinicalTrials.gov study NCT04744532. IPD Sharing: YES. Countries: 1. Publications: 2.
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
ClinicalTrials.gov study NCT04390464. IPD Sharing: Not stated. Countries: 1. Publications: 3.
tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
ClinicalTrials.gov study NCT05360264. IPD Sharing: NO. Countries: 1. Publications: 0.
Computational Drug Repurposing for All EBS Cases
ClinicalTrials.gov study NCT03269474. IPD Sharing: NO. Countries: 1. Publications: 17.
Data from: Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells
HIV persists because a reservoir of latently infected CD4 T cells do not express viral proteins and are indistinguishable from uninfected cells. One approach to HIV cure suggests that reactivating HIV will activate cytotoxic pathways; yet when tested in vivo, reactivating cells do not die sufficiently to reduce cell-associated HIV DNA levels. We recently showed that following reactivation from latency, HIV infected cells generate the HIV specific cytotoxic protein Casp8p41 which is produced by HIV protease cleaving procaspase 8. However, cell death is prevented, possibly due to low procaspase 8 expression. Here, we tested whether increasing procaspase 8 levels in CD4 T cells will produce more Casp8p41 following HIV reactivation, causing more reactivated cells to die. Screening 1277 FDA approved drugs identified 168 that increased procaspase 8 expression by at least 1.7-fold. Of these 30 were tested for anti-HIV effects in an acute HIVIIIb infection model, and 9 drugs at physiologic relevant levels significantly reduced cell-associated HIV DNA. Primary CD4 T cells from ART suppressed HIV patients were treated with one of these 9 drugs and reactivated with αCD3/αCD28. Four drugs significantly increased Casp8p41 levels following HIV reactivation, and decreased total cell associated HIV DNA levels (flurbiprofen: p = 0.014; doxycycline: p = 0.044; indomethacin: p = 0.025; bezafibrate: P = 0.018) without effecting the viability of uninfected cells. Thus procaspase 8 levels can be increased pharmacologically and, in the context of HIV reactivation, increase Casp8p41 causing death of reactivating cells and decreased HIV DNA levels. Future studies will be required to define the clinical utility of this or similar approaches.
Figure 3 from: Ayyar P, Subramanian U (2022) Repurposing – second life for drugs. Pharmacia 69(1): 51-59. https://doi.org/10.3897/pharmacia.69.e72548
Figure 3 A) Swanson's ABC model B) Signature similarity approach – Drug B has inverse signature similarity with the disease against which it is effective and drug A with similar signature to drug B can be potentially repurposed for the same disease C) Side effect similarity approach D) Associative indication transfer approach.
data for deep learning large-scale drug discovery and repurposing
Open the record for dataset details and reuse information.
Data from: Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis
Objective: To develop and implement an evidence based framework to select, from drugs already licenced, candidate oral neuroprotective drugs to be tested in secondary progressive multiple sclerosis. Design: Systematic review of clinical studies of oral putative neuroprotective therapies in MS and four other neurodegenerative diseases with shared pathological features, followed by systematic review and meta-analyses of the in vivo experimental data for those interventions. We presented summary data to an international multi-disciplinary committee, which assessed each drug in turn using pre-specified criteria including consideration of mechanism of action. Results: We identified a short list of fifty-two candidate interventions. After review of all clinical and pre-clinical evidence we identified ibudilast, riluzole, amiloride, pirfenidone, fluoxetine, oxcarbazepine, and the polyunsaturated fatty-acid class (Linoleic Acid, Lipoic acid; Omega-3 fatty acid, Max EPA oil) as lead candidates for clinical evaluation. Conclusions: We demonstrate a standardised and systematic approach to candidate identification for drug rescue and repurposing trials that can be applied widely to neurodegenerative disorders.
Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19
<p><strong>Introduction:</strong> In the randomized double-blind placebo-controlled CounterCOVID study, oral imatinib treatment<br> conferred a positive clinical outcome and a signal for reduced mortality in COVID-19 patients. High concen-<br> trations of alpha-1 acid glycoprotein (AAG) were observed in these patients and were associated with increased<br> total imatinib concentrations.<br> <strong>Aims:</strong> This post-hoc study aimed to compare the difference in exposure following oral imatinib administration in<br> COVID-19 patients to cancer patients and assess assocations between pharmacokinetic (PK) parameters and<br> pharmacodynamic (PD) outcomes of imatinib in COVID-19 patients. We hypothesize that a relatively higher drug<br> exposure of imatinib in severe COVID-19 patients leads to improved pharmacodynamic outcome parameters.<br> <strong>Methods:</strong> 648 total concentration plasma samples obtained from 168 COVID-19 patients were compared to 475<br> samples of 105 cancer patients, using an AAG-binding model. Total trough concentration at steady state (Cttrough)<br> and total average area under the concentration-time curve (AUCtave) were associated with ratio between partial<br> oxygen pressure and fraction of inspired oxygen (P/F), WHO ordinal scale (WHO-score) and liberation of oxygen<br> supplementation (O2lib). Linear regression, linear mixed effects models and time-to-event analysis were adjusted<br> for possible confounders.<br> <strong>Results:</strong> AUCtave and Cttrough were respectively 2.21-fold (95%CI 2.07–2.37) and 1.53-fold (95%CI 1.44–1.63)<br> lower for cancer compared to COVID-19 patients. Cttrough, not AUCtave, associated significantly with P/F<br> (β=-19,64; p-value=0.014) and O2lib (HR 0.78; p-value= 0.032), after adjusting for sex, age, neutrophil-<br> lymphocyte ratio, dexamethasone concomitant treatment, AAG and baseline P/F-and WHO-score. Cttrough, but<br> not AUCtave associated significantly with WHO-score. These results suggest an inverse relationship between PK-<br> parameters, Cttrough and AUCtave, and PD outcomes.<br> <strong>Conclusion:</strong> COVID-19 patients exhibit higher total imatinib exposure compared to cancer patients, attributed to<br> differences in plasma protein concentrations. Higher imatinib exposure in COVID-19 patients did not associate<br> with improved clinical outcomes. Cttrough and AUCtave inversely associated with some PD-outcomes, which may be biased by disease course, variability in metabolic rate and protein binding. Therefore, additional PKPD an-<br> alyses into unbound imatinib and its main metabolite may better explain exposure-response.</p>
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
ClinicalTrials.gov study NCT05125224. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.